Since these diseases are also associated with obesity, insulin resistance, and dyslipidemia47, TonEBP inhibition would provide a multipronged therapeutic approach to a host of complicated metabolic and inflammatory diseases. This evidence concerns the gene NFAT5 and obesity disorder.